CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results

CytomX Therapeutics (NASDAQ:CTMX) issued its earnings results on Thursday. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45, Zacks reports. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%.

CytomX Therapeutics Stock Up 0.3 %

Shares of CTMX stock traded up $0.00 on Thursday, hitting $0.62. The company had a trading volume of 902,249 shares, compared to its average volume of 2,401,818. The firm has a market cap of $48.31 million, a P/E ratio of 3.63 and a beta of 1.01. CytomX Therapeutics has a twelve month low of $0.60 and a twelve month high of $5.85. The company has a 50-day moving average price of $0.86 and a 200-day moving average price of $1.03.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.